Taysha Gene Therapies Income Statement (2022-2025) | TSHA

Income Statement Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025
Revenue & cost
Revenue -0.67M-0.74M-1.08M-1.30M4.71M2.40M4.75M3.60M3.41M1.11M1.79M2.02M2.30M1.99M-0.01M
Operating items
Research & Development 38.18M23.51M16.77M12.71M12.51M19.79M11.79M12.68M20.66M15.07M14.95M15.32M15.56M20.14M25.75M
Selling, General & Administrative 11.47M9.87M8.68M7.34M8.75M5.99M8.59M6.72M7.08M7.34M7.90M6.63M8.16M8.60M8.28M
Other Operating Expenses 36.42M0.62M0.45M4.84M
Operating Expenses 49.65M33.37M25.46M56.47M21.27M25.78M21.00M19.85M27.74M22.41M27.69M21.95M23.72M28.74M34.02M
Operating Income -49.65M-33.37M-25.46M-53.97M-16.56M-23.38M-16.25M-16.25M-24.33M-21.30M-25.90M-19.93M-21.42M-26.75M-34.02M
EBIT -49.65M-33.37M-25.46M-53.97M-16.56M-23.38M-16.25M-16.25M-24.33M-21.30M-25.90M-19.93M-21.42M-26.75M-34.02M
Non-operating items
Interest & Investment Income 0.01M0.03M0.01M0.20M0.32M0.22M1.11M1.92M1.69M1.44M2.11M1.70M1.33M1.86M3.17M
Other Non Operating Income -0.01M-0.00M-0.01M-0.01M0.00M100.46M-65.74M0.34M-0.20M-0.08M-0.18M-0.10M0.27M0.29M
Non Operating Income -0.67M-0.72M-1.07M-1.11M-1.06M-1.21M-100.84M63.99M0.27M0.37M0.37M1.15M-0.11M-0.24M1.29M
Net income details
EBT -50.31M-34.09M-26.53M-55.07M-17.61M-24.60M-16.61M-15.04M-22.67M-19.89M-23.82M-18.25M-20.11M-24.91M-30.87M
Profit After Tax -50.32M-34.09M-26.53M-55.08M-17.62M-24.60M-117.09M47.74M-24.06M-20.93M-25.52M-18.79M-21.53M-26.88M-32.73M
Income from Continuing Operations -50.31M-34.09M-26.53M-55.07M-17.61M-24.60M-16.61M-15.04M-22.67M-19.89M-23.82M-18.25M-20.11M-24.91M-30.87M
Consolidated Net Income -50.31M-34.09M-26.53M-55.07M-17.61M-24.60M-16.61M-15.04M-22.67M-19.89M-23.82M-18.25M-20.11M-24.91M-30.87M
Income towards Parent Company -50.31M-34.09M-26.53M-55.07M-17.61M-24.60M-16.61M-15.04M-22.67M-19.89M-23.82M-18.25M-20.11M-24.91M-30.87M
Net Income towards Common Stockholders -50.32M-34.09M-26.53M-55.08M-17.62M-24.60M-117.09M47.74M-24.06M-20.93M-25.52M-18.79M-21.53M-26.88M-32.73M
Additional items
EPS (Basic) -1.32-0.85-0.65-0.99-0.28-0.38-0.930.92-0.10-0.09-0.10-0.07-0.08-0.09-0.09
EPS (Weighted Average and Diluted) -1.32-0.85-0.65-0.99-0.28-0.38-0.930.92-0.10-0.09-0.10-0.07-0.08-0.09-0.09
Shares Outstanding (Weighted Average) 38.47M40.55M41.09M62.44M63.47M64.18M64.47M186.96M187.02M187.02M204.94M205.00M214.66M214.66M272.79M
Shares Outstanding (Diluted Average) 38.17M40.14M40.94M43.95M63.26M64.24M125.70M116.12M231.25M232.82M267.82M250.13M269.31M297.99M353.31M
EBITDA -49.65M-33.37M-25.46M-53.97M-16.56M-23.38M-16.25M-16.25M-24.33M-21.30M-25.90M-19.93M-21.42M-26.75M-34.02M
Interest Expenses 0.67M0.74M1.08M1.30M1.37M1.44M1.47M0.71M0.03M0.03M0.02M0.02M0.02M0.02M0.01M